AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Female
Ovarian Cancer
Female
Ovarian Cancer
Trial Information
AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or
primary peritoneal cancer not previously treated with chemotherapy
- Initiating Avastin in combination with chemotherapy
Exclusion Criteria:
- Contraindications, warnings and precautions for use as specified in the Avastin
Summary of Product Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival, defined as time from first administration of first-line therapy to documented disease progression
Outcome Time Frame:
approximately 6 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
United Kingdom: Department of Health
Study ID:
ML28570
NCT ID:
NCT01863693
Start Date:
May 2013
Completion Date:
August 2018
Related Keywords:
- Ovarian Cancer
- Ovarian Neoplasms
Name | Location |
|---|
